Background: Obesity is a worldwide epidemic that is difficult to control with non-invasive treatments, which usually present poor results. In this context, the intragastric balloon (IGB) is an important tool that presents a mean body weight loss (BWL) estimated at approximately 12%, although individual responses are highly variable.

Objectives: This study assesses whether there are factors that can predict responses to IGB therapy either before or early after placement of the device.

Materials And Methods: A total of 50 obese patients underwent insertion of IGB placed endoscopically, and patients were monitored for 6 months. The evaluated predictive factors involved general characteristics and psychological, social, and dyspeptic aspects, and the preliminary results obtained in the first month after balloon placement.

Results: The mean weight loss was 11.5%, and 48% of the participants presented BWL >10%. Among the factors analyzed before IGB placement, only advanced age (P = .04) and higher scores obtained in the social relationships domain of a shorter version of the World Health Organization's Quality of Life questionnaire (P = .02) were significant. Analysis of the factors evaluated after IGB placement revealed that the BWL amounts observed in week 2 (P = .001) and week 4 (P < .001) and the intensity of dyspeptic symptoms in week 2 (P < .001) were positive predictive factors.

Conclusions: The assessment of predictive factors may help to manage patients with IGB.

Download full-text PDF

Source
http://dx.doi.org/10.1089/lap.2015.0305DOI Listing

Publication Analysis

Top Keywords

intragastric balloon
8
weight loss
8
igb placement
8
factors
5
igb
5
assessment predictive
4
predictive response
4
response factors
4
factors intragastric
4
balloon therapy
4

Similar Publications

Background: Acute pancreatitis (AP) is a rare but serious complication of intragastric balloon (IGB) therapy. Despite the popularity of IGBs for weight loss, the incidence and risk factors of AP post-IGB insertion are not well understood. This study aimed to identify potential predictors and risk factors of AP in IGB patients.

View Article and Find Full Text PDF

Clinical Outcomes in Patients Undergoing Sequential Intragastric Balloon (IGB) Treatment for Super Obesity: A Single Centre Retrospective Analysis.

J Metab Bariatr Surg

December 2024

Department of General Surgery, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, Yorkshire, United Kingdom.

Purpose: We aimed to assess outcomes in patients undergoing sequential intragastric balloon (IGB) treatment for obesity.

Materials And Methods: Consecutive patients who underwent treatment between May 2014 and February 2023 were identified. We recorded outcomes including: weight at 3-monthly intervals, progression to definitive bariatric procedure and morbidity.

View Article and Find Full Text PDF

Tacrine is a centrally active non-competitive reversible acetylcholinesterase inhibitor. It also exerts antagonising activity against -methyl-D-aspartate receptors. Tacrine was approved for the treatment of Alzheimer's disease in 1993, but was withdrawn from clinical use in 2013 because of its hepatotoxicity and gastrointestinal side effects.

View Article and Find Full Text PDF

Background: Endoscopic bariatric interventions are viable alternatives to traditional weight loss surgeries for patients with a body mass index between 30 and 40 kg/m. While studies have explored the impact of intragastric balloons on obesity and weight reduction, comprehensive data on real-world device-related complications and failures are limited. This study aimed to investigate mechanical failures leading to patient adverse events reported to the US Food and Drug Administration.

View Article and Find Full Text PDF

Introduction: More than 40% of Americans are considered obese, resulting in annual healthcare costs estimated at $173 billion., Various interventions exist to address obesity including lifestyle modification, medications, and several surgical options. A novel ingestible intragastric balloon that self-deflates and is excreted approximately four months post-ingestion is being used in other countries such as Australia, Mexico, and several European countries.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!